Identification and management of cardiometabolic risk in Canada: A position paper by the cardiometabolic risk working group (Executive summary)

Lawrence A. Leiter, David H. Fitchett, Richard E.Gilbert Gupta, G. B.John Mancini, Philip A. McFarlane, Robert Ross, Subodh Verma, Sonia Anand, Kathryn Camelon, Chi Ming Chow, Jafna L. Cox, Jean Pierre Després, Jacques Genest, Stewart B. Harris, David C.W. Lau, Richard Lewanczuk, Peter P. Liu, Eva M. Lonn, Ruth McPherson, Paul PoirierShafiq Qaadri, Rémi Rabasa-Lhoret, Simon W. Rabkin, Arya M. Sharma, Andrew W. Steele, James A. Stone, Jean Claude Tardif, Sheldon Tobe, Ehud Ur

Résultat de recherche: Articleexamen par les pairs

49 Citations (Scopus)

Résumé

With the objectives of clarifying the concepts related to "cardiometabolic risk," "metabolic syndrome" and "risk stratification" and presenting practical strategies to identify and reduce cardiovascular risk in multiethnic patient populations, the Cardiometabolic Working Group presents an executive summary of a detailed analysis and position paper that offers a comprehensive and consolidated approach to the identification and management of cardiometabolic risk. The above concepts overlap and relate to the atherogenic process and development of type 2 diabetes. However, there is confusion about what these terms mean and how they can best be used to improve our understanding of cardiovascular disease treatment and prevention. The concepts related to cardiometabolic risk, pathophysiology, and strategies for identification and management (including health behaviours, pharmacotherapy, and surgery) in the multiethnic Canadian population are presented. "Global cardiometabolic risk" is proposed as an umbrella term for a comprehensive list of existing and emerging factors that predict cardiovascular disease and/or type 2 diabetes. Health behaviour interventions (weight loss, physical activity, diet, smoking cessation) in people identified at high cardiometabolic risk are of critical importance given the emerging crisis of obesity and the consequent epidemic of type 2 diabetes. Vascular protective measures (health behaviours for all patients and pharmacotherapy in appropriate patients) are essential to reduce cardiometabolic risk, and there is growing consensus that a multidisciplinary approach is needed to adequately address cardiometabolic risk factors. Health care professionals must also consider ethnicity-related risk factors in order to appropriately evaluate all individuals in their diverse patient populations.

Langue d'origineEnglish
Pages (de-à)124-131
Nombre de pages8
JournalCanadian Journal of Cardiology
Volume27
Numéro de publication2
DOI
Statut de publicationPublished - 2011

Note bibliographique

Funding Information:
Funding for this project was provided by the following organizations in the form of unrestricted educational grants: AstraZeneca Canada Inc, Boehringer Ingelheim (Canada) Ltd, Bristol-Myers Squibb Canada, Eli Lilly Canada Inc, GlaxoSmithKline Canada, Hoffmann-La Roche Ltd, Merck Frosst Canada Ltd, Merck Frosst/Schering Pharmaceuticals, Novartis Pharmaceuticals, Novo Nordisk Canada, Pfizer Canada Inc, Sanofi-Aventis Canada Inc, Servier Canada Inc. Corporate sponsors were not involved in the decision to publish this position paper, review of the literature, or development or review of any of the drafts.

ASJC Scopus Subject Areas

  • Cardiology and Cardiovascular Medicine

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review

Empreinte numérique

Plonger dans les sujets de recherche 'Identification and management of cardiometabolic risk in Canada: A position paper by the cardiometabolic risk working group (Executive summary)'. Ensemble, ils forment une empreinte numérique unique.

Citer